Alpha Cognition Inc. announced that it has filed a new composition-of-matter patent that secures broad protection for its lead asset, ALPHA-1062, currently under review by the FDA for mild-to-moderate Alzheimer's Disease. The present composition-of-matter patent application is filed for approval with the USPTO and may be extended to pursue protection throughout the world and, if approved, will secure composition-of-matter protection for an oral formulation of ALPHA-1062. The filing was based on novel and unexpected findings in the clinical trial work the company completed and further demonstrates the uniqueness of ALPHA-1062; If approved, the patent will provide protection for ALPHA-1062 into 2044, adding to other patent protection that currently protect ALPHA-1062 through 2042.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.79 CAD | 0.00% |
|
+5.33% | +19.70% |
May. 15 | Alpha Cognition Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 04 | Alpha Cognition's Q4 Comprehensive Loss Widens A Bit From Year Earlier Period | MT |
![Consensus](/images/consensus_flch.gif)
1st Jan change | Capi. | |
---|---|---|
+19.70% | 87.36M | |
+23.50% | 45.01B | |
+47.19% | 40.96B | |
-5.16% | 38.62B | |
+36.37% | 32.6B | |
-7.79% | 27.49B | |
+18.06% | 27.17B | |
+47.29% | 14.61B | |
+41.91% | 12.95B | |
-1.02% | 11.36B |
- Stock Market
- Equities
- ACOG Stock
- News Alpha Cognition Inc.
- Alpha Cognition Inc. Files Composition-Of-M Matter Patent